Malignancy in myositis

Zaki Abou Zahr, Alan Baer

Research output: Contribution to journalArticle

Abstract

Dermatomyositis is associated with an underlying malignancy in about 24% of cases. This association is also true for polymyositis but is less prominent. The malignancy is usually an adenocarcinoma of the ovary, lung, or gastrointestinal tract in Western countries and nasopharyngeal carcinoma in Southeast Asia, Southern China, and Northern Africa. Factors predictive of malignancy in myositis patients include more severe skin and muscle disease and the absence of overlap connective tissue disease features, such as interstitial lung disease. Anti-p155/140 antibodies have a strong predictive value for malignancy in adult patients. Patients with dermatomyositis or polymyositis require an evaluation for occult malignancy at the time of diagnosis and, in some cases, in the event of a subsequent recurrence. This paraneoplastic phenomenon may stem from an immune reaction to antigens expressed in both cancer cells and regenerating fibers in affected muscle.

Original languageEnglish (US)
Pages (from-to)208-215
Number of pages8
JournalCurrent Rheumatology Reports
Volume13
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

Myositis
Neoplasms
Dermatomyositis
Southern Africa
Polymyositis
Northern Africa
Muscles
Southeastern Asia
Interstitial Lung Diseases
Skin Diseases
Gastrointestinal Tract
Ovary
China
Antigens
Recurrence
Antibodies

Keywords

  • Dermatomyositis
  • Malignancy
  • Paraneoplastic syndrome
  • Polymyositis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Malignancy in myositis. / Zahr, Zaki Abou; Baer, Alan.

In: Current Rheumatology Reports, Vol. 13, No. 3, 06.2011, p. 208-215.

Research output: Contribution to journalArticle

Zahr, Zaki Abou ; Baer, Alan. / Malignancy in myositis. In: Current Rheumatology Reports. 2011 ; Vol. 13, No. 3. pp. 208-215.
@article{cb354469e61e47cc887d473911bb6c0c,
title = "Malignancy in myositis",
abstract = "Dermatomyositis is associated with an underlying malignancy in about 24{\%} of cases. This association is also true for polymyositis but is less prominent. The malignancy is usually an adenocarcinoma of the ovary, lung, or gastrointestinal tract in Western countries and nasopharyngeal carcinoma in Southeast Asia, Southern China, and Northern Africa. Factors predictive of malignancy in myositis patients include more severe skin and muscle disease and the absence of overlap connective tissue disease features, such as interstitial lung disease. Anti-p155/140 antibodies have a strong predictive value for malignancy in adult patients. Patients with dermatomyositis or polymyositis require an evaluation for occult malignancy at the time of diagnosis and, in some cases, in the event of a subsequent recurrence. This paraneoplastic phenomenon may stem from an immune reaction to antigens expressed in both cancer cells and regenerating fibers in affected muscle.",
keywords = "Dermatomyositis, Malignancy, Paraneoplastic syndrome, Polymyositis",
author = "Zahr, {Zaki Abou} and Alan Baer",
year = "2011",
month = "6",
doi = "10.1007/s11926-011-0169-7",
language = "English (US)",
volume = "13",
pages = "208--215",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Malignancy in myositis

AU - Zahr, Zaki Abou

AU - Baer, Alan

PY - 2011/6

Y1 - 2011/6

N2 - Dermatomyositis is associated with an underlying malignancy in about 24% of cases. This association is also true for polymyositis but is less prominent. The malignancy is usually an adenocarcinoma of the ovary, lung, or gastrointestinal tract in Western countries and nasopharyngeal carcinoma in Southeast Asia, Southern China, and Northern Africa. Factors predictive of malignancy in myositis patients include more severe skin and muscle disease and the absence of overlap connective tissue disease features, such as interstitial lung disease. Anti-p155/140 antibodies have a strong predictive value for malignancy in adult patients. Patients with dermatomyositis or polymyositis require an evaluation for occult malignancy at the time of diagnosis and, in some cases, in the event of a subsequent recurrence. This paraneoplastic phenomenon may stem from an immune reaction to antigens expressed in both cancer cells and regenerating fibers in affected muscle.

AB - Dermatomyositis is associated with an underlying malignancy in about 24% of cases. This association is also true for polymyositis but is less prominent. The malignancy is usually an adenocarcinoma of the ovary, lung, or gastrointestinal tract in Western countries and nasopharyngeal carcinoma in Southeast Asia, Southern China, and Northern Africa. Factors predictive of malignancy in myositis patients include more severe skin and muscle disease and the absence of overlap connective tissue disease features, such as interstitial lung disease. Anti-p155/140 antibodies have a strong predictive value for malignancy in adult patients. Patients with dermatomyositis or polymyositis require an evaluation for occult malignancy at the time of diagnosis and, in some cases, in the event of a subsequent recurrence. This paraneoplastic phenomenon may stem from an immune reaction to antigens expressed in both cancer cells and regenerating fibers in affected muscle.

KW - Dermatomyositis

KW - Malignancy

KW - Paraneoplastic syndrome

KW - Polymyositis

UR - http://www.scopus.com/inward/record.url?scp=79957448881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957448881&partnerID=8YFLogxK

U2 - 10.1007/s11926-011-0169-7

DO - 10.1007/s11926-011-0169-7

M3 - Article

C2 - 21336621

AN - SCOPUS:79957448881

VL - 13

SP - 208

EP - 215

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 3

ER -